(This document is a summary English translation of the original Japanese document. If there are any discrepancies between this document and the original Japanese document, the original Japanese document prevails.)

February 26, 2025

Company name: ROHTO Pharmaceutical Co., Ltd.
Representative: Masashi Sugimoto, President and COO
(Code: 4527 TSE Prime)
Contact: Masaya Saito, Vice President and CFO
(TEL:06-6758-8223)

Notice Regarding Repurchase of Shares (Repurchase of Shares pursuant to Provision of Articles of Incorporation in accordance with Article 459, Paragraph 1 of the Companies Act)

ROHTO PHARMACEUTICAL CO., LTD. (the "Company") hereby announces that the pursuant to a resolution of the Board of Directors as of February 26, 2025, the Company has resolved to repurchase its own shares as follows, pursuant to the provision of Article 459, Paragraph 1 of the Companies Act thereof.

1. Reason for Repurchase of Shares

The Company intends to repurchase its own shares in order to improve return on equity and earnings per share, as well as for smoothly carrying out fundraising by mitigating the short-term impact on demand and supply for the Company's Shares accompanied by the issuance of the Zero Coupon Convertible Bonds due 2032.

2. Matters regarding Repurchase

(1)	Class of Shares to be Repurchased	Common stock
(2)	Total Number of Shares which may be Repurchased	Up to 2,430,000 shares (approximately 1.07% of the total issued shares as of December 31, 2024 (excluding treasury stock))
(3)	Total Repurchase Price of Shares	Up to ¥5 billion
(4)	Repurchase Period	From February 27, 2025 to April 30, 2025
(5)	Repurchase Method	Market purchase (including an off-auction

Note: This press release is intended as general information regarding ROHTO Pharmaceutical Co., Ltd.'s repurchase of its own shares. This press release does not constitute an offer to purchase or subscribe for, or the solicitation of an offer to purchase or subscribe for the Company's convertible bonds with stock acquisition rights (the "Bonds") or the shares of common stock of the Company in the United States or in any jurisdiction in which such offer or solicitation is unlawful. In particular, the Bonds and the shares of common stock of the Company issuable upon exercise of the stock acquisition rights (together, the "Securities") have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any relevant securities laws of any state or other jurisdictions of the United States, and any such Securities may not be offered or sold within the United States, absent registration or an exemption from registration under the Securities Act, and in compliance with any applicable state or local securities laws; any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company. No public offering of the Securities will be made in the United States.

purchase transaction) at the Tokyo Stock Exchange

(Note) The purchase order may not be implemented, in whole or in part, depending on market conditions and other factors.

(Reference)

Status of Treasury Stock as of December 31, 2024

Total Issued Shares (Excluding Treasury Stock): 228,138,738 shares

Number of Treasury Stock: 8,039,572 shares

Note: This press release is intended as general information regarding ROHTO Pharmaceutical Co., Ltd.'s repurchase of its own shares. This press release does not constitute an offer to purchase or subscribe for, or the solicitation of an offer to purchase or subscribe for the Company's convertible bonds with stock acquisition rights (the "Bonds") or the shares of common stock of the Company in the United States or in any jurisdiction in which such offer or solicitation is unlawful. In particular, the Bonds and the shares of common stock of the Company issuable upon exercise of the stock acquisition rights (together, the "Securities") have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any relevant securities laws of any state or other jurisdictions of the United States, and any such Securities may not be offered or sold within the United States, absent registration or an exemption from registration under the Securities Act, and in compliance with any applicable state or local securities laws; any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company. No public offering of the Securities will be made in the United States.